Navigation Links
Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/6/2012

ancial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

About Amylin PharmaceuticalsAmylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin is committed to delivering novel therapies that transform the way diabetes, obesity and related metabolic disorders are treated. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, Calif., and has a commercial manufacturing facility in Ohio. More information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN or BYDUREON, and the revenues or royalties generated from these products, may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that the unaudited financial results set forth in this press release could differ materially from our year-end audited financial results; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results, may not be predictive of real world use or may not achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates or sNDAs for label expansion requests, may not be submit
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Novel t reatments   entering the ... GBI Research . ... driven primarily by the introduction of numerous premium therapies, particularly ... or combine with generic chemotherapies. Analysis from business ... Market to 2020 - forecasts the value of the ...
(Date:6/1/2015)... , June 1, 2015 Symbiotix Biotherapies, ... $2.3 million Phase 2 Small Business Technology Transfer (STTR) ... National Institute of Allergy and Infectious Diseases (NIAID). The ... developing a novel class of molecular therapeutics from ... clinical candidate, Polysaccharide A (PSA), is the first molecule ...
(Date:6/1/2015)... June 1, 2015   OTC Markets Group ... and Connected financial marketplaces for 10,000 U.S. and ... San Diego -based biopharmaceutical company, on ... America,s only public venture market for entrepreneurial and ... http://photos.prnewswire.com/prnh/20110118/MM31963LOGO "We,re happy to ...
Breaking Medicine Technology:New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3Symbiotix Biotherapies Announces $2.3 Million Award from NIH's National Institute of Allergy and Infectious Diseases (NIAID) 2OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... /PRNewswire-Asia/ -- Bristol-Myers Squibb Company (NYSE: ... (NYSE: SCR ), a leading pharmaceutical company ... the strategic partnership formed last year to include a ... agreed to co-develop BMS-795311, Bristol-Myers Squibb,s preclinical small molecule ...
... SAN DIEGO, Dec. 13, 2011  BioMed Realty Trust, Inc. ... has entered into a definitive agreement to acquire Prudential ... Street properties.  BioMed previously acquired a 20% interest in ... venture entered into between BioMed and PREI.  The Rogers ...
Cached Medicine Technology:Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound 2Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound 3Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound 4Biomed Realty Trust to Acquire Remaining 80% Interest in Rogers Street Properties in Cambridge, Massachusetts for $308 Million - Increasing Ownership to 100% 2Biomed Realty Trust to Acquire Remaining 80% Interest in Rogers Street Properties in Cambridge, Massachusetts for $308 Million - Increasing Ownership to 100% 3Biomed Realty Trust to Acquire Remaining 80% Interest in Rogers Street Properties in Cambridge, Massachusetts for $308 Million - Increasing Ownership to 100% 4
(Date:6/1/2015)... Linda Kincaid, age 67, knew something was wrong. She constantly ... thought it was just a part of getting older, but ... After going to the doctor, she received a distressing diagnosis: ... might happen to her. , Linda is not alone. As ... each year. Valve disease involves damage to one or more ...
(Date:6/1/2015)... Portland, Ore. (PRWEB) June 01, 2015 ... Plans (AHIP) announced today a new, interactive Affordable ... support large employers. The course, called “Affordable Care ... care professionals with the strategic and consultative insights ... employers as they navigate the impacts of the ...
(Date:6/1/2015)... NY (PRWEB) June 01, 2015 For ... patients requesting celebrity features. Much like one would request ... stars’ noses, eyes, cheeks, chin and more to illustrate ... filtering apps like FaceTune are ushering in a new ... Manhattan facial plastic surgeon, Sam Rizk, MD, FACS notes ...
(Date:6/1/2015)... June 01, 2015 Listen to Volvo’s ... automotive companies are using more granular data to create ... comparatively new industry voices in Josep Celaya Gonzalez, CIO ... start-up ParkTAG. As an automotive insurer, MAPFRE are well ... an easy-to-use solution to the driver. Award winning start-up ...
(Date:6/1/2015)... 2015 A University of Texas ... signaling proteins that activate protein degradation, which helps ... 1 , The study published April 3rd ... Spraque-Dawley rats 2-3 months of age who performed ... given either whey protein (.4g/kg), low-dose Sustamine (.1g/kg), ...
Breaking Medicine News(10 mins):Health News:A New Online Resource for Those Living with Heart Valve Disease 2Health News:A New Online Resource for Those Living with Heart Valve Disease 3Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2Health News:Complimentary Webinar: Volvo, MAPFRE and Award Winning Start-Up discuss new Frontier of In-Car Services 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 3
... of poor children with congenital heart diseases (CHD) here moved ... the US by a non-profit organization. About 40-50 NRIs have ... keen to sponsor a child or two every year ... born in India with CHD. Only six to eight percent ...
... devised a new system that ranks foods according to ... and developed// by a panel of independent nutritionists, dietitians, ... as well as members of the government’s Scientific Advisory ... developed by the UK’s Food Standards Agency (FSA) has ...
... change in the genetic constitution is what makes each ... is unraveled, then health care can be individualized according ... same genetic code, how those genes express themselves at ... medicines and dietary advice. According to a recent study, ...
... among couples who smoke according to a new study// which ... stroke than cigarette-smoking women with non-smoking spouses. ,The study ... total stroke and ischemic stroke (a stroke caused by a ... groups of women. The relative risk of total stroke was ...
... fine combing of wet hair may be far more ... ,Researchers have used single blind randomized controlled trial ... counter insecticide treatments against head lice in United Kingdom. ... more effective than current over the counter chemical treatments ...
... with severe asthma according to a recent study.// This ... of antioxidants such as vitamin C and incidence of ... intakes and blood concentrations of antioxidants, including vitamin C, ... without asthma. , ,Men with severe asthma had ...
Cached Medicine News:Health News:Nutrient Profiling System Launched By Food Officials in UK 2Health News:Learning Just How Different We Are 2Health News:Combing Hair More Effective Than OTC Medicine For Head Lice 2
Coibri handle. Pierse tips with 6 mm platform. 2.5 mm angled tips. Manufactured in titanium....
Straight shafts with 2.0 mm, 1 x 2 Elschnig style teeth. Serrated handle with polished finish. Handle: Wide....
Straight shafts with 45 degrees, 0.12 mm, 2 x 3 teeth and tying platform. Serrated handle with polished finish....
Straight shafts with 0.1 mm Pierse tips. Flat smooth handle with dull finish....
Medicine Products: